Zendal Group holds the first edition of the International Zendal Awards

  • The awards were created with the aim to spread, promote and reward to knowledge and research in the area of biotechnology all over the world

Vigo, the 23rd of July 2019. Zendal Group has opened the first calling for the International Zendal Awards with the aim of recognising the work of those institutions, public or private, that develop their work both in animal and in human healthcare, and that have shown distinction and commitment in the field of vaccines, prevention and biotechnology.

“We know that behind every advancement in the area of healthcare and science there is a tremendous amount of work and effort, thus, from Zendal we want to pay homage to those public and private institutions that are working daily to improve healthcare and research”, pointed out the Managing Director of the Group, Andrés Fernández Álvarez-Santullano, who is convinced that “These improvements are the driving force for progress in society”.

The entities who wish to present their nomination can do so until the coming 4th of October via a form posted in www.zendal.es, where they can also consult the bases for the awards. The award to the best project will have a prizemoney of 5,000 euros, that will be invested in implementing the submitted proposal.

Tribute to a scientific personality

The Zendal Awards ceremony will take place on the 28th of November in Vigo. During the act a tribute will also be made to a scientific personality who has contributed to improving human and veterinary healthcare throughout their career.

Ir a premios

Sobre Zendal

Zendal es un grupo biofarmacéutico cien por cien español que aglutina a siete empresas enfocadas en la investigación, el desarrollo, la fabricación y la comercialización de productos de alto valor añadido en el ámbito de la biotecnología, las vacunas y la salud: CZ Vaccines, Biofabri, Vetia, Petia, Zinereo Pharma, Bialactis y Probisearch.